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Aim: Hyperhomocysteinemia has been associated with different pathologies, including cardiovascular diseases, hypertension, dia-
betes, and breast cancer (BC). To examine the differences in total homocysteine (tHcy) plasma levels, we compared healthy women 
to BC patients from a Mexican population. Materials and Methods: The tHcy plasma levels were measured using high-performance 
liquid chromatography with a fluorescence detector in 89 female controls and 261 BC patients. Results: The observed plasma tHcy 
levels were significantly higher among the BC patients (11.1019 ± 5.9161 µmol/l) compared to the controls (9.1046 ± 1.3213 µmol/l) 
(p = 0.002), and these differences were evident when stratified by age (≥ 50 years old), menopause status, overweight and obesity, 
miscarriages, node metastases, progression, subtype classification (luminal, Her2 and triple negative) and nonresponse to che-
motherapy. Conclusions: The tHcy plasma levels could be a good marker for the progression and chemosensitivity of BC in the 
analyzed sample from a Mexican population.
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Breast cancer (BC) is a significant public health 
problem worldwide [1], and its incidence varies among 
different ethnic groups [2–4]. In Mexico, BC is respon-
sible for 19% of mortality in women > 20 years old 
and in general is considered one of the major causes 
of death [4]. A study that projected cancer incidence 
to 2030 in Mexico estimated that there will be approxi-
mately 13,981 new cases annually, of which 38% will 
occur in women older than 65 years [4]. BC develops 
through a gradual accumulation of genetic and epi-
genetic changes that transform normal breast cells 
into invasive cancer tissues [5]. In this sense, previ-
ous studies have reported the relationship between 
hyperhomocysteinemia (HHcy) and BC [6–8].
Homocysteine (Hcy) is a sulfur amino acid pre-
cursor of the demethylation of methionine, and 
it is degraded by remethylation or transsulfuration [7]. 
Vitamins B6 and B12 and folate are important cofac-
tors that participate in the metabolism of Hcy [9]. Hcy 
is present as a monomer or a dimer (Hcy-Hcy, Hcy-
cysteine) and is mainly bound to a protein fraction (al-
bumin; 80–85%) [10]. Hcy also plays an important role 
in methylation and the provision of nucleotides for DNA 
synthesis. The insufficient input of folates produces 
elevated plasma concentrations of Hcy and S-adeno-
sylmethionine (SAM); thus, SAM acts as an inhibitor 
of the methyltransferase enzyme. This inhibition alters 
both the DNA methylation process and the regulation 
of gene expression, and consequently participates 
in the oncogenesis on the genetic level [11].
Conversely, different factors can affect Hcy levels 
such as age, gender, menopause, pregnancy, tobacco 
and alcohol consumption, ethnic group and deficiency 
of enzymes involved in the methionine to cysteine 
metabolism. The reference ranges of Hcy, in healthy 
individuals, are determined by standardization in each 
laboratory [12, 13]. Some studies have associated 
HHcy with BC [8] with low folate levels [14], meta-
stasis [15], and chemotherapy response [16]. How-
ever, in the Mexican population, these associations 
remain unknown. Thus, the aim of this investigation 
was to determine the HHcy plasma levels in Mexican 
BC patients.
MATERIALS AND METHODS
Blood samples were collected from 89 healthy 
female blood donor volunteers and from 261 pa-
tients with clinically and histologically confirmed 
BC. All patients were residents of the metropolitan 
area of Guadalajara and were recruited from June 
2014 to May 2017. All samples were obtained after 
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the patients signed a written informed consent, previ-
ously approved by the ethics committee (IMSS 1305). 
All procedures performed in studies involving human 
participants were in accordance with the 1964 Declara-
tion of Helsinki. All included individuals were unrelated. 
Clinical and demographic data were obtained using 
written questionnaires. All patients were interviewed 
to determine their occupational exposure and current 
drug regimens.
tHcy quantification was performed by the HPLC-
fluorescence method (Agilent 1100 series HPLC 
system equipped with an isocratic pump, thermostat, 
automatic injector, model 1100 fluorometric detec-
tor system controlled by the ChemStation software), 
according to a modified method described previ-
ously [17], using 7-fluoro-2,1,3-benzoxadiazole-
4-sulfonate (SBD-F, Sigma-Aldrich, St. Louis, MO, 
USA) as the derivatizing agent.
The plasma samples were separated by centrifuga-
tion (3,500 rpm × 10 min) at room temperature within 
30 min after collection and stored at −20 °C until be-
ing processed. To separate tHcy, 50 μl of plasma 
sample, 25 μl of 1X PBS (phosphate buffered saline) 
and 40 μl of Tris (2-carboxyethyl) phosphine hydro-
chloride 25 g/l (TCEP, Sigma-Aldrich, St. Louis, MO, 
USA) were incubated for 30 min at room temperature 
in an Eppendorf tube for thiol reduction. Subsequently, 
90 μl of trichloroacetic acid-ethylenediaminetetraace-
tic acid (TCA-EDTA 0.6 M and 0.0012 M, respectively) 
was added and mix for 30 s for proteins precipitation. 
After centrifugation at 13,000 g for 10 min at room 
temperature, from the supernatant 50 μl were taken, 
and then 40 μl of 0.39 M NaOH, 125 μl of borate-EDTA 
buffer (0.005 M EDTA and 0.125 M boric acid) and 
50 μl of g/l SBD-F derivatizing agent were added. The 
mixture was homogenized and incubated for 60 min 
at 60 °C in a light-protected water bath. Filter sample 
by 0.45 μm Millipore filter and injected into the chro-
matograph.
Acetate buffer (mixture of 0.083 M sodium acetate 
and 0.05 M acetic acid, adjusting the pH to 5.5 with 
NaOH) was used as the mobile phase in an Eclipse 
C18 column (150 × 4.6 mm, 5 μm). The fluorometric 
detector had a length (λex) of 385 nm for excitation 
and 515 nm for emission. The validation process was 
conducted following the guidelines for biological 
sample analyses [18].
All statistical analyses were performed using the 
PASW Statistic Base 18 software, 2009 (Chicago, IL, 
USA). Sample t-tests or the Mann — Whitney U test 
were performed to compare the means of a continuous 
variable across dichotomized variables. All statistical 
tests were two-tailed, and p values less than 0.05 were 
considered statistically significant.
RESULTS
Table 1 shows the comparative epidemiological data 
from the BC patients and the control individuals. The ob-
served average age was 53.3 ± 11.4 years in the patient 
group and 52.6 ± 15.5 years in the control group; non-
significant differences were observed. However, the 
tHcy plasma levels were significantly different between 
the patients and controls (p = 0.002), and they remained 
significantly different when stratified by ≥ 50 years old 
(p = 0.015) and menopause status (p = 0.007).
Table 1. Comparison of Hcy plasma levels in BC patients and controls
Characteristics BC patients Controls p-value*tHcy, µmol/l (mean ± SD)
Age, years 53.3065 ± 11.4427 
(n = 261)
52.6180 ± 15.4636 
(n = 89)
0.656
tHcy 11.1019 ± 5.9161 
(n = 261)
9.1046 ± 1.3213 
(n = 89)
0.002
tHcy (< 50 years 
old)
10.4886 ± 4.4830 
(n = 89)
9.0317 ± 1.4298 
(n = 38)
0.053
tHcy (≥ 50 years 
old) 
11.4193 ± 6.5251 
(n = 172)
9.1590 ± 1.2461 
(n = 51)
0.015
tHcy (tobacco 
consumption) 
10.4485 ± 3.2310 
(n = 72)
9.2481 ± 1.5462 
(n = 19)
0.120
tHcy (alcohol con-
sumption) 
10.0792 ± 3.3334 
(n = 38)
9.0777± 1.4435 
(n = 18)
0.229
tHcy (menopause) 11.4408 ± 6.5051 
(n = 173)
9.1014± 1.2387 
(n = 59)
0.007
tHcy (premeno-
pause) 
10.4358 ± 4.5012 
(n = 88)
9.1109± 1.4929 
(n = 30)
0.117
Notes: SD — standard deviation; *Student’s t-test.
When stratified and compared by menopause 
and pre-menopause status and alcohol and tobacco 
consumption, there were no significant differences 
between the patients and the controls (Table 1). Sig-
nificant differences were found in tHcy plasma levels 
between BC patients, stratified by clinical charac-
teristics, compared to the control group (Table 2). 
Non-significant differences in tHcy plasma levels 
were found between BC groups stratified by clinical 
characteristics.
DISCUSSION
In Mexico, BC is currently one of the leading 
causes of disease and death in women [1–4]. In the 
present study, we observed that the mean age of the 
BC patients was 53.3 ± 11.4 years. Many studies have 
observed a high incidence of BC in patients who were 
approximately 50 years old [1–5, 19].
Lifestyle changes and expanded longevity likely 
have an influence on the increased frequency of this 
disease in the Mexican population [3, 19, 20].
Knowledge of how Hcy metabolism affects breast 
molecular carcinogenesis is important; relevant stu-
dies have reported that HHcy in women with low folate 
status affects gene expression and promotes cell 
proliferation in the oncogenesis of breast cells [5–10, 
14–16, 21]. However, the relationship between HHcy 
and BC remains controversial and possibly depends 
on the population being studied and ambient factors 
including lifestyles and food and toxic exposition that 
can influence the promotion of tumoral epigenetic 
changes [15, 22].
Moreover, little is known regarding tHcy levels 
in Mexican BC patients. In our study group, the Hcy 
levels (mean ± SD) were 9.1046 ± 1.3213 μmol/l in con-
trols and 11.1019 ± 5.9161 μmol/l in BC patients, which 
indicates the presence of HHcy in BC (p = 0.002); these 
data are consistent with other studies in BC [8, 15, 16, 
21]. Furthermore, the tHcy levels in women ≥ 50 years 
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old and with menopause status differed between the 
control group and the BC patients (p = 0.015).
Some studies suggest that HHcy is related to indi-
vidual differences such as gender, diet, alcohol con-
sumption and smoking habits [15, 21, 23]. Others 
established that HHcy was more evident in older sub-
jects than in younger subjects [24]. In fact, the HHcy 
in BC patients ≥ 50 years old observed in this study 
could be due to the average age of our BC patients 
and may also be influenced by hormonal effects, which 
can modulate plasma Hcy [24, 25].
Hcy metabolism may regulate the expression 
of distinct pathways required in tumoral behavior, 
which has been demonstrated in previous studies 
in BC [14, 21]. A hypothesis by Zhu et al. [26] proposes 
that HHcy is a risk factor for estrogen induced tumori-
genesis: HHcy causes the intracellular accumulation 
of S-adenosylhomocysteine (SAH), which induces the 
production of oxidative metabolites of estrogens (cate-
chol estrogens) that contribute to estrogen-induced 
tumors in animal models and in some human cancers 
such as BC [7].
Nevertheless, HHcy is considered a risk factor 
in BC patients with increased body mass index (BMI; 
overweight, obesity). A variety of mechanisms for 
obesity and HHcy have been proposed that could 
contribute to the development of BC [27].
In addition to these mechanisms, several factors 
could influence the development of BC. As a previous 
study has suggested, different dietary patterns may 
contribute to the observed differences in Hcy, which 
could upset the balance between the production and 
degradation of Hcy, resulting in HHcy [27]. These 
results suggest that the dietary pattern of studied 
population is rich in fat, food processing and freez-
ing, which could contribute to weight gain in women 
with BC. In fact, there are several theories that at-
tempt to explain this association, involving the role 
of leptin, insulin and other molecules that mediate the 
inflammatory process, independent of estrogen and 
HHcy [20]. Hcy may inhibit endothelial cell growth, 
increasing oxidative stress and promoting inflamma-
tory processes in adipocytes, which could collectively 
accelerate oncogenesis in BC [28]. Adipocytes are 
now recognized as active endocrine cells that produce 
hormones, growth factors, and cytokines. In fact, the 
most likely scenario is that these mechanisms may 
act in combination to explain the relationship linking 
menopause and subsequent weight gain as a risk 
factor for BC progression and mortality [20]. It is well 
established that folate deficiency results in HHcy. 
Hence, in folate-deficient individuals, decreased levels 
of tetrahydrofolate (THF) cofactors (e.g., 5-CH3-THF) 
limit metabolic flux through the methionine synthase 
reaction, with the consequent accumulation of Hcy, 
the substrate of this enzyme [29].
Samples analyzed in this study showed that the 
factors associated with HHcy were age (≥ 50 years 
old), menopause and BMI (overweight and obesity), 
factors that are risk indicators for different patholo-
gies including BC (Tables 1 and 2). These factors are 
closely related since estrogen production is lower 
in older women, which consequently results in over-
weight or obesity, and obesity is related to menopause 
because of a greater endogenous estrogen produc-
tion. This, in turn, is related to the altered metabolism 
of Hcy. Thus, estrogens stimulate the metabolism 
of methionine by transamination and in turn increase 
the catabolism of Hcy [30].
The association of HHcy with miscarriages 
in BC patients was evident in the present study. This 
relationship is not well established in previously stu-
dies; however, some studies have observed HHcy 
in recurrent abortions [31]. HHcy may be consequence 
of an interaction between a genetic defect (presence 
of mutations in enzymes that participate in folate 
Table 2. Comparison of Hcy plasma levels by clinical characteristics of BC patients and controls
Clinical characteristics tHcy, µmol/l (mean ± SD)BC patients Controls (n = 89) p-value*
BIM** Overweight (18.5–24.9 kg/m2) (n = 86) 10.7126 ± 5.0415 9.1046 ± 1.3213 0.002
Obesity I (25–29.9 kg/m2) (n = 69) 12.1896 ± 9.2362 0.001
Obesity II (30–34.9 kg/m2) (n = 27) 11.1674 ± 4.0041 0.001
Obesity III (35–39.9 kg/m2) (n = 9) 11.0708 ± 1.6192 0.001
Miscarriages (n = 86)*** 10.7473 ± 3.7162 0.001
Node metastasis (n = 183) 11.5412 ± 6.7426 0.001
Stage I (n = 14) 10.0079 ± 3.1161 0.062
II (n = 76) 10.8486 ± 8.1610 0.049
III (n = 81) 10.9711 ± 4.8267 0.001
IV (n = 86) 11.4978 ± 4.7680 0.001
HC Triple negative (n = 89) 10.0293 ± 3.6542 0.033
Luminal A (n = 114) 11.4753 ± 7.8658 0.005
Luminal B (n = 56) 11.6637 ± 4.3413 0.001
HER2 (n = 42) 10.5910 ± 2.8378 0.001
Ki-67 (n = 173) 10.7807 ± 6.1952 0.012
Chemotherapy Before (n = 47) 14.0525 ± 10.3094 0.001
After (n = 214) 10.4539 ± 4.17458 0.003
NR (n = 13) **** 14.1158 ± 8.76301 0.001
MR (n = 38) 10.7665 ± 3.35320 0.001
NRR (n = 47) 11.3949 ± 4.79354 0.001
Notes: SD — standard deviation; HC — histologic classification; *Student’s t-test; **according to OMS classifications (appropriate body-mass index for Asian 
populations and its implications for policy and intervention strategies. Genève (Switzerland): World Health Organization, 2004); NRR — nonresponse che-
motherapy by recurrence; ***≥ 2 loss gestational; ****NR — non-chemotherapy response; MR — minimal chemotherapy response; NRR — non-chemothe-
rapy response by recurrence. The nonresponse to treatment with (epirubicin-cyclophosphamide-5-fluorouracil) and capecitabine was evaluated according 
to the pathological Ryan’s classification described as follows: 1. Moderate response (single cells or small groups of cancerous cells); 2. Minimum response 
(residual cancer surrounded by fibrosis); and 3. Poor response (minimal or no tumor destruction, extensive residual cancer).
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metabolism), a nutrition condition (folate deficiency), 
and preeclampsia, which could be a putative cause 
of recurrent miscarriages [31].
HHcy and node metastasis, Ki-67 and advanced 
cancer stages (III and IV) were also statistically signifi-
cant in our BC patients. A variety of HHcy mechanisms 
could contribute to the development of metastasis. 
In fact, a significant correlation has been observed 
between the number of Ki-67 positive cells and tumor 
cell proliferation [32]. Other authors have suggested 
that the activation and proliferation of immunocompe-
tent cells are responsible for HHcy in BC and throm-
boembolic events in patients with malignancies [33]. 
Moreover, a strong staining of folate receptor alpha 
in Stage IV BC has been observed, suggesting the 
necessity of folates demands in advanced tumoral 
progression [34, 35].
We observed the presence of HHcy in luminal 
(A and B), HER2 and triple negative cases. In addition, 
there are other studies that support our findings [35]. 
HHcy was observed in BC patients, with no response 
to adjuvant chemotherapy, contained such chemo-
therapeutic drugs as capecitabine (oral drug) and 
epirubicin-cyclophosphamide-5-fluorouracil (pro-
drug) that are commonly given to BC patients. The al-
kylating agents of chemotherapy would affect folic acid 
and B12 vitamin concentrations, resulting in increased 
Hcy concentrations, which act on DNA by affecting 
synthesis and cell division. Folic acid antagonists, 
such as capecitabine and 5-fluorouracil, inhibit both 
dihydrofolate reductase and folate-dependent en-
zymes in the synthesis of nucleic acids, consequently 
HHcy alter the pharmacological efficiency of chemo-
therapeutic agents interfering their action mechanism, 
which affects the response in BC. Furthermore, some 
neoplastic cell receptors have an affinity to folates; 
thus, they are dependent on the folate concentra-
tion, and HHcy can cause a lack of sufficient supplies. 
The chemosensitivity of patients with BC differs from 
person to person, which reflects the limited advances 
in our understanding of the molecular mechanisms 
underlying breast carcinogenesis and the individual 
susceptibility to this disease and its treatment [19].
Folate metabolism can likely influence the chemo-
therapy response in addition to other factors, such 
as a known presence of metastatic nodes, tumor 
markers, menopause, the time of diagnosis, tumor 
stage, and treatment resistance [19]. This response 
might be affected by polymorphisms in genes that 
participate in folate metabolism, which could lead 
to a dysregulation in the metabolite concentration, 
thus producing changes in DNA and subsequently 
participating in neoplastic progression. Aberrant 
DNA methylation is recognized as a common feature 
of human neoplasia, with CpG island hypermethy-
lation and global genomic hypomethylation occur-
ring simultaneously in tumors. Because it affects 
the methylation of DNA and tumor suppressor genes, 
the MTHFR polymorphism could potentially modulate 
the efficacy of cytotoxic agents [20, 21, 25]. More-
over, the response to drugs is not only related to the 
monogenic inheritance of a protein but also depends 
on genes encoding proteins involved in multiple meta-
bolic pathways, posttranslational modifications, gene 
interactions, and epigenetic regulation [21].
Unfortunately, the status of folate, vitamin B and 
die tary intake of the individuals were not analyzed 
in this study. Nonetheless, the results suggest that 
an appropriate dietary folates intake can reduce 
BC risk in older women, which could be reflected 
in progression and susceptibility to chemotherapy.
In conclusion, our results showed that when com-
paring HHcy levels in BC patients and controls, the 
differences were more evident with the following cha-
racteristics: 1) ≥ 50 years old; 2) menopause; 3) BMI 
overweight and obesity; 4) miscarriages; 5) node me-
tastases; 6) progression; 7) luminal, HER2 and triple 
negative; and 8) nonresponse to chemotherapy, 
confirming that tHcy plasma levels could be a good 
marker of BC and that these factors contribute signifi-
cantly to BC in the analyzed sample from a Mexican 
population. Further studies are required to confirm 
these observations.
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